Morepen Laboratories' Q1 FY 2026-27 Quarterly Results

Result Summary

• Morepen Laboratories Ltd reported a 16.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 33.9%.
• Its expenses for the quarter were up by 6.6% QoQ and 20.9% YoY.
• The net profit increased 258.9% QoQ and increased 424.2% YoY.
• The earnings per share (EPS) of Morepen Laboratories Ltd stood at 1.03 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Morepen Laboratories Ltd is a well-established company in the pharmaceutical and healthcare industry. The company is primarily engaged in the manufacturing and marketing of various pharmaceutical products, including active pharmaceutical ingredients (APIs), branded formulations, and over-the-counter (OTC) products. Morepen Laboratories has a significant presence in the healthcare sector, focusing on producing quality drugs and healthcare solutions. The company is known for its expertise in the production of APIs, which are used by pharmaceutical companies globally. There are no specific recent major developments available for Morepen Laboratories Ltd as of the latest data.

Revenue

The financial data for Morepen Laboratories Ltd indicates a robust growth in total income for the quarter ending Q1FY27, amounting to ₹575.31 crores. This marks a 16.7% increase from the previous quarter, Q4FY26, which reported a total income of ₹493.18 crores. Year-over-year, the total income saw a substantial increase of 33.9% compared to Q1FY26, where the total income was ₹429.65 crores. This consistent growth in income highlights the company's strong revenue-generating capabilities over the recent quarters and year.

Profitability

In terms of profitability, Morepen Laboratories Ltd reported a significant increase in its profit before tax, with Q1FY27 seeing a total of ₹74.53 crores. This represents a 220.0% increase from the previous quarter, Q4FY26, which recorded ₹23.29 crores, and a remarkable 380.2% rise year-over-year from ₹15.52 crores in Q1FY26. After accounting for taxes, the profit after tax for Q1FY27 was ₹56.35 crores, reflecting a 258.9% increase from ₹15.70 crores in the previous quarter and a 424.2% rise from ₹10.75 crores in Q1FY26. The earnings per share also followed a similar upward trend, rising to ₹1.03 in Q1FY27 from ₹0.28 in Q4FY26 and ₹0.20 in Q1FY26, showcasing a substantial growth both quarter-over-quarter and year-over-year.

Operating Metrics

The operating metrics for Morepen Laboratories Ltd demonstrate a notable increase in total expenses, which amounted to ₹500.78 crores in Q1FY27. This represents a 6.6% increase from the previous quarter, Q4FY26, where expenses were ₹469.90 crores, and a 20.9% increase year-over-year compared to ₹414.14 crores in Q1FY26. Despite the rise in expenses, the company's profit margins have improved significantly, as indicated by the higher profits before and after tax. The tax expenses also increased to ₹18.18 crores in Q1FY27 from ₹7.59 crores in Q4FY26 and ₹4.11 crores in Q1FY26, showing a rise of 139.5% quarter-over-quarter and 342.3% year-over-year. These metrics provide insights into the company's operational efficiency and cost management strategies over the quarters.